Daphnetin ameliorates intervertebral disc degeneration via the Keap1/Nrf2/NF-κB axis in vitro and in vivo
International Immunopharmacology · 2025-01 · 145 · 113785
DOI: 10.1016/j.intimp.2024.113785 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025-01. Verfasst von Shunlun Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, PR China. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Intervertebral Disc Degeneration, Umbelliferones, NF-E2-Related Factor 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Guizhou Medical University, Guizhou Provincial Health Commission, Health Commission of Guizhou Province.
Abstract (Originalsprache)
Intervertebral disc degeneration (IVDD) is the primary cause of low back pain (LBP). Enhanced inflammation and reactive oxygen species (ROS) levels can cause apoptosis, which is one of the initial factors of IVDD. Our previous study showed that daphnetin (DAP) alleviates IVDD; however, the underlying mechanisms remain unknown. An IVDD mouse model was established by lumbar disc puncture to investigate the mechanisms of DAP regulation, and DAP was injected intraperitoneally. Moreover, nucleus pulposus cells (NPCs) were challenged with tumor necrosis factor-alpha (TNF-α)/H2O2 to mimic IVDD. Additionally, NPC apoptosis, ROS, and the expression of proinflammatory cytokines were comprehensively assessed. We found that DAP can reverse H2O2-induced ROS and play an anti-inflammatory role by inhibiting Nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. Moreover, we found that DAP inhibits the apoptosis of NPCs induced by H2O2/TNF-α. DAP may regulate ROS production and apoptosis via the Kelch-like ECH-associated protein 1/NF-E2-related factor 2/heme oxygenase-1 (Keap1/Nrf2/HO-1) pathway. These findings were confirmed by in vivo results. The comprehensive nature of our research provides a strong foundation for the potential use of DAP as a therapeutic agent to alleviate IVDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, PR China.
- Department of Spinal Surgery, First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, PR China.
- Department of Spine Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, PR China.
- Beijing Jishuitan Hospital Guizhou Hospital.
- School of Clinical Medicine, Guizhou Medical University, Guiyang 550004, PR China.
- Department of Spine Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, PR China. Electronic address: wangh227@mail.sysu.edu.cn.
Förderung
- Guizhou Medical University
- Guizhou Provincial Health Commission
- Health Commission of Guizhou Province
- Foundation for Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Chen, S., Huang, Y., Lei, L., Yang, C., Ran, D., Zhou, E., Wang, H., & Ning, X. (2025). Daphnetin ameliorates intervertebral disc degeneration via the Keap1/Nrf2/NF-κB axis in vitro and in vivo. International Immunopharmacology, 145, 113785. https://doi.org/10.1016/j.intimp.2024.113785
Vancouver
Chen S, Huang Y, Lei L, Yang C, Ran D, Zhou E, et al. Daphnetin ameliorates intervertebral disc degeneration via the Keap1/Nrf2/NF-κB axis in vitro and in vivo. International Immunopharmacology. 2025;145:113785. doi:10.1016/j.intimp.2024.113785
BibTeX
@article{Chen2025,
author = {Chen, Shunlun and Huang, Yuming and Lei, Linchuan and Yang, Cheng and Ran, Dongcheng and Zhou, Enyu and Wang, Hua and Ning, Xu},
title = {Daphnetin ameliorates intervertebral disc degeneration via the Keap1/Nrf2/NF-κB axis in vitro and in vivo},
journal = {International Immunopharmacology},
year = {2025},
volume = {145},
pages = {113785},
doi = {10.1016/j.intimp.2024.113785}
}
EUVIMED